sotagliflozin
Commercial- Indications
- Type 1 diabetes, Type 2 diabetes
Company intelligence / Profile preview
Ambra BioScience
San Marcos, California, United Stateslinkedin.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
Ambra BioScience has developed proprietary GSM technology for commercial dietary supplements and medical foods aimed at supporting healthy weight and blood sugar. No clinical trial results are referenced in the available sources.
- Therapeutic areas
- Metabolic DisordersEndocrinologyGastroenterology
- Modalities
- Dietary supplementsmedical foods; utilizes Gut Sensory Modulation (GSM) technology[1]
- Industry
- Food & Nutrition
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ambra BioScience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambra BioScience.